Bronstein, Gewirtz & Grossman, LLC Files Class Action Lawsuit Against Actinium Pharmaceuticals, Inc.
On April 14, 2025, Bronstein, Gewirtz & Grossman, LLC, a prominent law firm, announced the filing of a class action lawsuit against Actinium Pharmaceuticals, Inc. (“Actinium” or “the Company”) (NYSE:ATNM) and certain of its officers. The lawsuit alleges violations of the federal securities laws, seeking to recover damages on behalf of all persons and entities that purchased or otherwise acquired Actinium securities between March 31, 2022, and August 2, 2024.
Class Definition
The class action lawsuit, filed in the United States District Court for the Southern District of New York, aims to recover damages against Defendants for their alleged misrepresentations and omissions during the Class Period. The Class Period refers to the time frame between March 31, 2022, and August 2, 2024.
Allegations Against Actinium and Its Officers
The complaint alleges that Actinium and its officers made false and misleading statements regarding the Company’s business, operational, and financial developments. Specifically, the lawsuit alleges that the defendants failed to disclose material information concerning the Company’s financial condition, clinical trial results, and regulatory approvals.
Impact on Actinium Shareholders
The filing of this class action lawsuit may have significant implications for Actinium shareholders. If the allegations are proven true, shareholders may be entitled to compensation for their losses. The lawsuit may also negatively impact Actinium’s stock price, potentially causing further financial harm to shareholders.
Global Consequences
The repercussions of this class action lawsuit extend beyond Actinium and its shareholders. The lawsuit may lead to increased scrutiny of the biopharmaceutical industry, as well as heightened awareness of the importance of accurate and timely disclosures. The outcome of this case could also set a precedent for future securities litigation.
Conclusion
The filing of a class action lawsuit against Actinium Pharmaceuticals, Inc. and certain of its officers for alleged securities law violations may have significant consequences for the Company’s shareholders and the biopharmaceutical industry as a whole. As the case progresses, further information will be made available. Bronstein, Gewirtz & Grossman, LLC encourages anyone with a significant loss from investing in Actinium between March 31, 2022, and August 2, 2024, to contact the firm for a free consultation.
- Actinium Pharmaceuticals, Inc. and certain officers face a class action lawsuit alleging securities law violations.
- The lawsuit seeks damages on behalf of all persons and entities that purchased Actinium securities between March 31, 2022, and August 2, 2024.
- Allegations include misrepresentations and omissions regarding Actinium’s business, operational, and financial developments.
- Impact on Actinium shareholders may include potential compensation and negative stock price effects.
- Global consequences include increased industry scrutiny and potential precedent-setting outcomes.
